Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, July 2000, p. 1911-1916, Vol. 44, No. 7
Faculté de Pharmacie, Université
Henri Poincaré, Nancy 1, UMR-CNRS 7564, LCPE Biochimie
Microbienne, 54001 Nancy Cedex,1 and
Groupe de Recherches sur les Interactions Moléculaires,
EA 2402, Université Henri Poincaré, Nancy 1, 54511 Vandoeuvre les Nancy Cedex,2 France
Received 13 July 1999/Returned for modification 30 September
1999/Accepted 17 April 2000
The membrane fluidity of reduced-amphotericin B (AmB)-sensitivity
Kluyveromyces lactis mutant strain is higher than that of the wild-type K. lactis strain. After culture of the
K. lactis and K. lactis mutant cells in the
presence of subinhibitory doses of AmB (10 and 125 mg/liter,
respectively), the plasma membranes of both yeast strains also showed a
higher fluidity than did those of control cells. High membrane fluidity
was associated with changes in the structural properties of the
membranes. Culture of the K. lactis and K. lactis mutant cells in the presence of AmB induced changes in
membrane lipid contents. In particular, phospholipid contents were
increased in both strains treated with AmB, compared with their
corresponding counterparts. As a result, the sterol/phospholipid ratio
decreased. The relative proportion of monounsaturated fatty acids also
increased after AmB treatment. The saturated fatty acid/monounsaturated
fatty acid ratio decreased in K. lactis and K. lactis mutant cells treated with AmB but also in K. lactis mutant control cells compared to that in the K. lactis wild strain. These changes in lipid composition explain
the higher fluidity, which could represent a process of metabolic
resistance of the yeasts to AmB.
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Amphotericin B Resistance and Membrane Fluidity in
Kluyveromyces lactis Strains
*
Corresponding author. Mailing address: Université
Henri Poincaré, Nancy 1, Faculté de Pharmacie, UMR-CNRS
7564, LCPE Biochimie Microbienne, 5 rue Albert Lebrun, B.P. 403, 54001 Nancy Cedex, France. Phone: 33(0)3-83-17-88-42. Fax:
33(0)3-83-17-88-79. E-mail: bonaly{at}pharma.u-nancy.fr.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»